The exclusive executive track session, “Cell and Gene Therapies at the Intersection of Business and Science,” will take place on May 14 at 9:30 a.m. during the AAPS National Biotechnology Conference (NBC) in San Francisco.
 
Potens Pharmaceuticals Founder Praveen Tyle, Ph.D., will moderate a panel focused on the current state of cell and gene therapies. The discussion will center on practical insights into how biotech leaders are addressing market pain points, e.g., global market access, development speed, and organizational capabilities. Other discussion points include business considerations and their intersection with scientific advancement, and how demand for these advanced therapeutics impacts global health.
 
“Cell and gene therapies represent the future of biotherapeutic drug development,” said Dr. Tyle, who is also Vice Chair of AAPS’s Business and Partner Development Committee. “Overcoming current challenges to ensure continued growth of these products requires science’s business leaders to come together and work collaboratively across the industry. I’m honored to facilitate this discussion at the NBC.”
 
Jason Bock, Ph.D., Co-Founder and CEO of the Cell Therapy Manufacturing Center (CTMC), Nianwei Lin, Ph.D., Co-Founder and President at iXCells Biotechnologies, and Kimberley Buytaert-Hoefen, Ph.D., Executive Director and Global Head of Regulatory Services at QPS, are confirmed to speak in this session.